Plasma levels of matrix metalloproteinase-9 are independently associated with psychosocial factors in a middle-aged normal population

Psychosomatic Medicine

Volumn 71, Issue 3, 2009, Pages 292-300

  Garvin, Peter ^a   Nilsson, Lennart ^a   Carstensen, John ^a   Jonasson, Lena ^a   Kristenson, Margareta ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Cardiovascular.; Cynicism; Depression; Hostile affect; Metalloproteinases; Sense of coherence

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; ENZYME; GELATINASE B;

ADULT; AGED; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; CORONARY ARTERY DISEASE; DEPRESSION; DIAGNOSTIC TEST; DISEASE ASSOCIATION; EMOTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; INTEGRATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEOPLASM; POPULATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; RISK FACTOR; RUPTURE; SELF ESTEEM; SEX; SOCIAL PSYCHOLOGY; AFFECT; BLOOD; HOSTILITY; MAJOR DEPRESSION; PSYCHOLOGICAL ASPECT; PSYCHOLOGY; SELF CONCEPT; SOCIAL SUPPORT;

AFFECT; AGED; CORONARY ARTERY DISEASE; DEPRESSIVE DISORDER, MAJOR; FEMALE; HOSTILITY; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PSYCHOLOGY; QUESTIONNAIRES; SELF CONCEPT; SOCIAL SUPPORT;

EID: 68549125231     PISSN: 00333174     EISSN: 15347796     Source Type: Journal    
DOI: 10.1097/PSY.0b013e3181960e7f     Document Type: Article

References (74)

1. Frasure-Smith N, Lesperance F. Reflections on depression as a cardiac risk factor. Psychosom Med 2005;67(Suppl);1:S19-S25.
2. Glassman AH, Shapiro PA. Depression and the course of coronary artery disease. Am J Psychiatry 1998;155:4-11.
3. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation 1999;99:2192-217.
4. Everson-Rose SA, Lewis TT. Psychosocial factors and cardiovascular diseases. Annu Rev Public Health 2005;26:469-500.
5. Matthews KA, Gump BB, Harris KF, Haney TL, Barefoot JC. Hostile behaviors predict cardiovascular mortality among men enrolled in the multiple risk factor intervention trial. Circulation 2004;109:66-70.
6. Chang PP, Ford DE, Meoni LA, Wang NY, Klag MJ. Anger in young men and subsequent premature cardiovascular disease: the precursors study. Arch Intern Med 2002;162:901-6.
7. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52.
8. Surtees PG, Wainwright NW, Luben R, Khaw KT, Day NE. Mastery, sense of coherence, and mortality: evidence of independent associations from the EPIC-Norfolk prospective cohort study. Health Psychol 2006;25:102-10.
9. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005;111:3481-8.
10. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
11. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
12. Gidron Y, Gilutz H, Berger R, Huleihel M. Molecular and cellular interface between behavior and acute coronary syndromes. Cardiovasc Res 2002;56:15-21.
13. Suarez EC. Plasma interleukin-6 is associated with psychological coronary risk factors: moderation by use of multivitamin supplements. Brain Behav Immun 2003;17:296-303.
14. Suarez EC. C-reactive protein is associated with psychological risk factors of cardiovascular disease in apparently healthy adults. Psychosom Med 2004;66:684-91.
15. Miller GE, Stetler CA, Carney RM, Freedland KE, Banks WA. Clinical depression and inflammatory risk markers for coronary heart disease. Am J Cardiol 2002;90:1279-83.
16. Sjogren E, Leanderson P, Kristenson M, Ernerudh J. Interleukin-6 levels in relation to psychosocial factors: studies on serum, saliva, and in vitro production by blood mononuclear cells. Brain Behav Immun 2006;20: 270-8. Epub 2005 Sep 23.
17. Steptoe A, Hamer M, Chida Y. The effects of acute psychological stress on circulating inflammatory factors in humans: a review and meta-analysis. Brain Behav Immun 2007;21:901-12. Epub 2007 May 1.
18. Kuo HK, Yen CJ, Chang CH, Kuo CK, Chen JH, Sorond F. Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol 2005;4:371-80.
19. Nabi H, Singh-Manoux A, Shipley M, Gimeno D, Marmot MG, Kivimaki M. Do psychological factors affect inflammation and incident coronary heart disease: the Whitehall II study. Arterioscler Thromb Vasc Biol 2008;28:1398-406.
20. Carney RM, Freedland KE, Miller GE, Jaffe AS. Depression as a risk factor for cardiac mortality and morbidity: a review of potential mechanisms. J Psychosom Res 2002;53:897-902.
21. Rozanski A, Blumenthal JA, Davidson KW, Saab PG, Kubzansky L. The epidemiology, pathophysiology, and management of psychosocial risk factors in cardiac practice: the emerging field of behavioral cardiology. J Am Coll Cardiol 2005;45:637-51.
22. Herrmann J, Lerman LO, Mukhopadhyay D, Napoli C, Lerman A. Angiogenesis in atherogenesis. Arterioscler Thromb Vasc Biol 2006;26: 1948-57.
23. Newby AC. Do metalloproteinases destabilize vulnerable atherosclerotic plaques? Curr Opin Lipidol 2006;17:556-61.
24. Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation 1995;91: 2125-31.
25. Hallenbeck JM, Hansson GK, Becker KJ. Immunology of ischemic vascular disease: plaque to attack. Trends Immunol 2005;26:550-6.
26. Kovanen PT, Kaartinen M, Paavonen T. Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation 1995;92:1084-8.
27. Fukuda D, Shimada K, Tanaka A, Kusuyama T, Yamashita H, Ehara S, Nakamura Y, Kawarabayashi T, Iida H, Yoshiyama M, Yoshikawa J. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. Am J Cardiol 2006;97:175-80.
28. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, Meyer J, Cambien F, Tiret L. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003;107:1579-85.
29. Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, Ueno T, Sugi K, Imaizumi T. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998;32:368-72.
30. Loftus IM, Goodall S, Crowther M, Jones L, Bell PR, Naylor AR, Thompson MM. Increased MMP-9 activity in acute carotid plaques: therapeutic avenues to prevent stroke. Ann N Y Acad Sci 1999;878: 551-4.
31. Nagase H, Visse R, Murphy G. Structure and function of matrix metal-loproteinases and TIMPs. Cardiovasc Res 2006;69:562-73.
32. Garvin P, Nilsson L, Carstensen J, Jonasson L, Kristenson M. Circulating matrix metalloproteinase-9 is associated with cardiovascular risk factors in a middle-aged normal population. PLoS ONE 2008;3:e1774.
33. Sillanaukee P, Kalela A, Seppa K, Hoyhtya M, Nikkari ST. Matrix metalloproteinase-9 is elevated in serum of alcohol abusers. Eur J Clin Invest 2002;32:225-9.
34. Kang MJ, Oh YM, Lee JC, Kim DG, Park MJ, Lee MG, Hyun IG, Han SK, Shim YS, Jung KS. Lung matrix metalloproteinase-9 correlates with cigarette smoking and obstruction of airflow. J Korean Med Sci 2003;18:821-7.
35. Yasmin, McEniery CM, Wallace S, Dakham Z, Pulsalkar P, Maki-Petaja K, Ashby MJ, Cockcroft JR, Wilkinson IB. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 2005;25:372.
36. Tayebjee MH, Nadar S, Blann AD, Gareth Beevers D, MacFadyen RJ, Lip GY. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian cardiac outcomes trial (ASCOT). Am J Hypertens 2004;17:764-9.
37. Liang KC, Lee CW, Lin WN, Lin CC, Wu CB, Luo SF, Yang CM. Interleukin-1beta induces MMP-9 expression via p42/p44 MAPK, p38 MAPK, JNK, and nuclear factor-kappaB signaling pathways in human tracheal smooth muscle cells. J Cell Physiol 2007;211:759-70.
38. Lu Y, Wahl LM. Production of matrix metalloproteinase-9 by activated human monocytes involves a phosphatidylinositol-3 kinase/Akt/IKKalpha/NF-kappaB pathway. J Leukoc Biol 2005;78:259-65.
39. Opdenakker G, Van den Steen PE, Dubois B, Nelissen I, Van Coillie E, Masure S, Proost P, Van Damme J. Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol 2001;69:851-9.
40. Aljada A, Ghanim H, Mohanty P, Hofmeyer D, Tripathy D, Dandona P. Hydrocortisone suppresses intranuclear activator-protein-1 (AP-1) binding activity in mononuclear cells and plasma matrix metalloproteinase 2 and 9 (MMP-2 and MMP-9). J Clin Endocrinol Metab 2001;86:5988-91.
41. Yang EV, Sood AK, Chen M, Li Y, Eubank TD, Marsh CB, Jewell S, Flavahan NA, Morrison C, Yeh PE, Lemeshow S, Glaser R. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res 2006;66:10357-64.
42. Eberhardt W, Schulze M, Engels C, Klasmeier E, Pfeilschifter J. Glucocorticoid-mediated suppression of cytokine-induced matrix metalloproteinase-9 expression in rat mesangial cells: involvement of nuclear factor-kappaB and Ets transcription factors. Mol Endocrinol 2002;16:1752-66.
43. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94: 2493-503.
44. Galis ZS, Asanuma K, Godin D, Meng X. N-acetyl-cysteine decreases the matrix-degrading capacity of macrophage-derived foam cells: new target for antioxidant therapy? Circulation 1998;97:2445-53.
45. Nikkari ST, Hoyhtya M, Isola J, Nikkari T. Macrophages contain 92-kd gelatinase (MMP-9) at the site of degenerated internal elastic lamina in temporal arteritis. Am J Pathol 1996;149:1427-33.
46. Hollman G, Kristenson M. The prevalence of the metabolic syndrome and its risk factors in a middle-aged Swedish population - mainly a function of overweight? Eur J Cardiovasc Nurs 2008;7:21-6.
47. Appels A, Kop W, Bar F, de Swart H, Mendes de Leon C. Vital exhaustion, extent of atherosclerosis, and the clinical course after successful percutaneous transluminal coronary angioplasty. Eur Heart J 1995;16:1880-5.
48. Barefoot JC, Dodge KA, Peterson BL, Dahlstrom WG, Williams RB Jr. The Cook-Medley hostility scale: item content and ability to predict survival. Psychosom Med 1989;51:46-57.
49. Surtees P, Wainwright N, Luben R, Khaw KT, Day N. Sense of coherence and mortality in men and women in the EPIC-Norfolk United Kingdom prospective cohort study. Am J Epidemiol 2003;158:1202-9.
50. Radloff L. The CES-D Scale. A self-report depression scale for research in the general population. Applied Psychological Measures 1977;1: 385-401.
51. Appels A, Hoppener P, Mulder P. A questionnaire to assess premonitory symptoms of myocardial infarction. Int J Cardiol 1987;17:15-24.
52. Pearlin LI, Schooler C. The structure of coping. J Health Soc Behav 1978;19:19.
53. Antonovsky A. Unraveling the Mystery of Health: How People Manage Stress and Stay Well. San Francisco: Jossey-Bass; 1987.
54. Orth-Gomer K, Unden AL. The measurement of social support in population surveys. Soc Sci Med 1987;24:83-94.
55. Gerlach RF, Demacq C, Jung K, Tanus-Santos JE. Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin Biochem 2007;40: 119-23.
56. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
57. Kubzansky LD, Cole SR, Kawachi I, Vokonas P, Sparrow D. Shared and unique contributions of anger, anxiety, and depression to coronary heart disease: a prospective study in the normative aging study. Ann Behav Med 2006;31:21-9.
58. Suarez EC. Joint effect of hostility and severity of depressive symptoms on plasma interleukin-6 concentration. Psychosom Med 2003;65:523-7.
59. Raynor DA, Pogue-Geile MF, Kamarck TW, McCaffery JM, Manuck SB. Covariation of psychosocial characteristics associated with cardiovascular disease: genetic and environmental influences. Psychosom Med 2002;64:191-203; discussion 204-5.
60. Kingwell BA, Medley TL, Waddell TK, Cole TJ, Dart AM, Jennings GL. Large artery stiffness: structural and genetic aspects. Clin Exp Pharmacol Physiol 2001;28:1040-3.
61. Cipollone F, Toniato E, Martinotti S, Fazia M, Iezzi A, Cuccurullo C, Pini B, Ursi S, Vitullo G, Averna M, Arca M, Montali A, Campagna F, Ucchino S, Spigonardo F, Taddei S, Virdis A, Ciabattoni G, Notarbartolo A, Cuccurullo F, Mezzetti A. A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA 2004;291:2221-8.
62. Uemura S, Matsushita H, Li W, Glassford AJ, Asagami T, Lee KH, Harrison DG, Tsao PS. Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res 2001;88:1291-8.
63. Kameda K, Matsunaga T, Abe N, Hanada H, Ishizaka H, Ono H, Saitoh M, Fukui K, Fukuda I, Osanai T, Okumura K. Correlation of oxidative stress with activity of matrix metalloproteinase in patients with coronary artery disease. Possible role for left ventricular remodelling. Eur Heart J 2003;24:2180-5.
64. Siwik DA, Pagano PJ, Colucci WS. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol 2001;280:C53-60.
65. Miller GE, Chen E, Zhou ES. If it goes up, must it come down? Chronic stress and the hypothalamic-pituitary-adrenocortical axis in humans. Psychol Bull 2007;133:25-45.
66. Pope MK, Smith TW. Cortisol excretion in high and low cynically hostile men. Psychosom Med 1991;53:386-92.
67. Ram M, Sherer Y, Shoenfeld Y. Matrix metalloproteinase-9 and autoimmune diseases. J Clin Immunol 2006;26:299-307.
68. Tchetverikov I, Lard LR, DeGroot J, Verzijl N, TeKoppele JM, Breedveld FC, Huizinga TW, Hanemaaijer R. Matrix metalloproteinases -3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann Rheum Dis 2003;62:1094-9.
69. Johansson N, Ahonen M, Kahari VM. Matrix metalloproteinases in tumor invasion. Cell Mol Life Sci 2000;57:5-15.
70. Hanemaaijer R, Sier CF, Visser H, Scholte L, van Lent N, Toet K, Hoekman K, Verheijen JH. MMP-9 activity in urine from patients with various tumors, as measured by a novel MMP activity assay using modified urokinase as a substrate. Ann N Y Acad Sci 1999;878:141-9.
71. Folkman J. Angiogenesis. Annu Rev Med 2006;57:1-18.
72. Derosa G, D'Angelo A, Scalise F, Avanzini MA, Tinelli C, Peros E, Fogari E, Cicero AF. Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome. Heart Vessels 2007;22:361-70.
73. Shiau MY, Tsai ST, Tsai KJ, Haung ML, Hsu YT, Chang YH. Increased circulatory MMP-2 and MMP-9 levels and activities in patients with type 1 diabetes mellitus. Mt Sinai J Med 2006;73:1024-8.
74. Okura Y, Urban LH, Mahoney DW, Jacobsen SJ, Rodeheffer RJ. Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol 2004;57:1096-103.